{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:02:16Z","timestamp":1776139336878,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clml.2024.12.012","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T19:47:46Z","timestamp":1735069666000},"page":"e253-e261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multiple Myeloma in Italy: An Epidemiological Model by Treatment Line and Refractoriness Status"],"prefix":"10.1016","volume":"25","author":[{"given":"Roberto","family":"Mina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mangiacavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-5251","authenticated-orcid":false,"given":"Gianni","family":"Ghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Pellizzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Iannello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2024.12.012_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.12.012_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.12.012_bib0003","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.12.012_bib0004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/14740338.2020.1733968","article-title":"The safety of current and emerging therapies for multiple myeloma","volume":"19","author":"Nadeem","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.clml.2024.12.012_bib0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.12.012_bib0006","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.12.012_bib0007","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.12.012_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2024.12.012_bib0009","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: ffindings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.12.012_bib0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cancers15010155","article-title":"How to manage patients with lenalidomide-refractory multiple myeloma","volume":"15","author":"De Arriba De La Fuente","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.clml.2024.12.012_bib0011","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1097\/HS9.0000000000000975","article-title":"Management and outcomes of anti-CD38 refractory patients: the impact of retreatment and of subsequent therapies","volume":"7","author":"Kastritis","year":"2023","journal-title":"HemaSphere"},{"issue":"5","key":"10.1016\/j.clml.2024.12.012_bib0012","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.12.012_bib0013","unstructured":"Ministry of Health. Determina n. DG\/754\/2018. GU Serie Generale n.119 del 24-05-2018. 2018. Accessed June 28, 2024. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2018-05-24&atto.codiceRedazionale=18A03534."},{"key":"10.1016\/j.clml.2024.12.012_bib0014","unstructured":"Ministry of Health. Determina n. DG\/4\/2021. GU Serie Generale n.10 del 14-01-2021. 2021. Accessed June 28, 2024. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2021-01-14&atto.codiceRedazionale=21A00064."},{"key":"10.1016\/j.clml.2024.12.012_bib0015","unstructured":"Ministry of Health. Determina n. DG\/1391\/2021. GU Serie Generale n.288 del 03-12-2021. 2021. Accessed June 28, 2024. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2021-12-03&atto.codiceRedazionale=21A07072."},{"key":"10.1016\/j.clml.2024.12.012_bib0016","unstructured":"ISTAT. Population Projection. 2024. Accessed June 28, 2024. https:\/\/demo.istat.it\/app\/?i=PPR&l=en."},{"key":"10.1016\/j.clml.2024.12.012_bib0017","unstructured":"GITMO. Transplant activity 2019-2020. 2021. Accessed June 28, 2024. https:\/\/www.gitmo.it\/storage\/gitmo\/article\/pdf\/65\/743-Transplant%20activity%202019%20e%202020.pdf."},{"issue":"8","key":"10.1016\/j.clml.2024.12.012_bib0018","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2217\/fon-2020-0970","article-title":"Estimate of multiple myeloma patients by line of therapy in the USA: population-level projections 2020\u20132025","volume":"17","author":"Kanas","year":"2021","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.12.012_bib0019","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjh.18658","article-title":"Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre","volume":"201","author":"Mor\u00e8","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.12.012_bib0020","unstructured":"AIOM-AIRTUM. I numeri del cancro in Italia 2021. 2022. Accessed June 28, 2024. https:\/\/www.aiom.it\/wp-content\/uploads\/2021\/10\/2021_NumeriCancro_web.pdf."},{"issue":"3","key":"10.1016\/j.clml.2024.12.012_bib0021","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Sch\u00fcrch","year":"2020","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.clml.2024.12.012_bib0022","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: aavailable therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.clml.2024.12.012_bib0023","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3390\/genes11121453","article-title":"A tangle of genomic aberrations drives multiple myeloma and correlates with clinical aggressiveness of the disease: a comprehensive review from a biological perspective to clinical trial results","volume":"11","author":"Sessa","year":"2020","journal-title":"Genes"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.12.012_bib0024","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1182\/blood-2022-163335","article-title":"Daratumumab plus Lenalidomide and Dexamethasone (D-Rd) versus Lenalidomide and Dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Maia study","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood"},{"issue":"10218","key":"10.1016\/j.clml.2024.12.012_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"10192","key":"10.1016\/j.clml.2024.12.012_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.clml.2024.12.012_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-018-3546-8","article-title":"Navigating the treatment landscape in multiple myeloma: which combinations to use and when?","volume":"98","author":"Goldschmidt","year":"2019","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.12.012_bib0028","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41375-019-0480-2","article-title":"Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m2 vs. twice-weekly 27 mg\/m2 carfilzomib (randomized A.R.R.O.W. study)","volume":"33","author":"Moreau","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.12.012_bib0029","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cancers15030962","article-title":"Attrition rates in multiple myeloma treatment under real world conditions-an analysis from the Austrian myeloma registry (AMR)","volume":"15","author":"Benda","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clml.2024.12.012_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-023-00883-x","article-title":"Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","volume":"13","author":"McCurdy","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2024.12.012_bib0031","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:10Z","timestamp":1762600630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2152265024024509"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Myeloma in Italy: An Epidemiological Model by Treatment Line and Refractoriness Status","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}